Picture loading failed.

Pre-Made Denosumab biosimilar, Whole mAb, Anti-TNFSF11/ODF Antibody: Anti-OPGL/sCD254/OPTB2/RANKL/TNLG6B/TRANCE/hRANKL2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-140-1mg 1mg 3090
GMP-Bios-ab-140-10mg 10mg Inquiry
GMP-Bios-ab-140-100mg 100mg Inquiry
GMP-Bios-ab-140-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Denosumab biosimilar, Whole mAb, Anti-TNFSF11/ODF Antibody: Anti-OPGL/sCD254/OPTB2/RANKL/TNLG6B/TRANCE/hRANKL2 therapeutic antibody
INN Name Denosumab
TargetODF
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2005
Year Recommended2006
CompaniesAmgen;Daiichi Sankyo Company;European Thoracic Oncology Platform;GlaxoSmithKline;Jules Bordet Institute;Melbourne Health;University Health Network
Conditions ApprovedBone cancer;Bone disorders;Bone metastases;Corticosteroid-induced osteoporosis;Male osteoporosis;Malignant hypercalcaemia;Osteoporosis;Postmenopausal osteoporosis;Rheumatoid arthritis
Conditions ActiveBreast cancer;Non-small cell lung cancer;Osteogenesis imperfecta;Malignant melanoma
Conditions DiscontinuedMultiple myeloma
Development TechAbgenix XenoMouse